Healthcare legislation boosts future of cancer care services
Oncology fared well under the new healthcare reform legislation without cuts to the core businesses of medical oncology, radiation oncology, office-administered drugs, and PET/PET-CT imaging.
BALTIMORE-Oncology fared well under the new healthcare reform legislation without cuts to the core businesses of medical oncology, radiation oncology, office-administered drugs, and PET/PET-CT imaging, according to a presenter at the 2010 Association of Community Cancer Centers meeting.
The new legislation will spend $940 billion over ten years to expand private insurance coverage and expand the privately insured patient population including those who require cancer care, said Matt Brow, vice president of government relations and public policy for US Oncology, based in the Woodlands, Tex.
Mr. Brow pointed out some of the provisions that directly affect oncology care:
Source: "Healthcare Reform: How Does Oncology Fare?,"
www.accc-cancer.org
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
